Introduction AMO Pharma Ltd. engages in the development of biopharmaceutical products. It develops and identifies and advance therapies for people affected by serious and debilitating diseases, particularly rare or orphan diseases. The company was founded by Michael F. Snape on February 10, 2015 and is headquartered in Leeds, United Kingdom. |
Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
Glutamates | 1 |
HDACs(Histone deacetylase) | 1 |
Target |
Mechanism RAS inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Glutamates modulators |
Active Org. AMO Pharma Ltd.Startup |
Originator Org. AMO Pharma Ltd.Startup |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HDAC inhibitors |
Active Org. AMO Pharma Ltd.Startup [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date23 Aug 2021 |
Sponsor / Collaborator AMO Pharma Ltd.Startup |
Start Date03 Mar 2021 |
Sponsor / Collaborator AMO Pharma Ltd.Startup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AMO-04 ( Glutamates ) | Rett Syndrome More | Phase 2 |
RND-001 ( HDACs ) | Niemann-Pick Disease, Type C More | Preclinical |
Diazepinomicin ( RAS x TSPO ) | Fragile X Syndrome More | Pending |
Tideglusib ( GSK-3β ) | Myotonic Dystrophy More | Pending |